Thryv Therapeutics has spent years building a single chemical scaffold into cardiac clinical assets. The CSIC/UAM license, effective July 1, 2026, gives it a structurally independent second scaffold, and the target now points at the brain: Parkinson’s disease, Alzheimer’s disease, and related tauopathies. A first development candidate from the new series is targeted for nomination in 2027, while the existing cardiac program runs in parallel.
The practical value of a second, distinct chemotype is that it lets Thryv separate optimization tracks. Its current molecules, built from a library of more than 500 synthesized analogs on the original scaffold, are advancing toward cardiac indications. THRV-1268 is now in the WAVE II study in Long QT Syndrome Type 2, with a Phase 2a heart failure trial (ASPIRE-HF) planned to follow. The new CSIC/UAM series was never designed to compete with that chemistry; it was designed from the start to cross into the central nervous system, where the cardiac compounds were not built to go.
SGK1 has published links to tau phosphorylation, misfolded protein handling, neuroinflammatory signaling, and FOXO- and NRF2-dependent stress responses, all pathways with direct relevance to Parkinson’s and Alzheimer’s. The research groups behind the licensed compounds span medicinal chemistry, neurobiology, cardiovascular biology, and vascular pharmacology at CSIC’s Centro de Investigaciones Biológicas Margarita Salas and UAM’s Institute for Biomedical Research. That breadth matters because CNS drug development typically requires the chemistry and the disease biology to be co-developed from early stages. Approved options for Alzheimer’s disease remain limited and recently expanded to include lecanemab maintenance dosing; for Parkinson’s, the treatment toolkit has been largely stable, with the FDA’s March 2026 labeling action on levodopa/carbidopa the most recent notable regulatory move. Neither disease has an approved therapy that addresses the kinase biology Thryv is targeting.
The concrete marker to track now is whether Thryv nominates a development candidate from the new series on its 2027 timeline, since that decision will signal whether the CNS program moves from platform expansion into something with a clinical path.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
